The Primary
Care Companionfor CNS Disorders

Advancing primary care with essential peer-reviewed research and insights into CNS disorders

Back to top Open menu arrow
Current Issue Archives Authors Reviewers
Non-Drug Treatment Landscape for GAD: Cognitive Therapies
news

Non-Drug Treatment Landscape for GAD: Cognitive Therapies

October 14, 2026

CBT has the strongest evidence among cognitive therapies for GAD, while support for applied relaxation and metacognitive therapy is less certain.
GAD Is More Common in Women, but Evidence Around Pregnancy and Menopause Remains Unclear
news

GAD Is More Common in Women, but Evidence Around Pregnancy and Menopause Remains Unclear

October 14, 2026

GAD is more common in women, but evidence that pregnancy or menopause alters GAD itself remains limited because studies mostly measured anxiety symptoms.
JCP
Bonus Episode: Lessons from Early Adopters of XT in Schizophrenia with Ilan Melnick, MD
Podcast

Bonus Episode: Lessons from Early Adopters of XT in Schizophrenia with Ilan Melnick, MD

October 13, 2026

Dr. Ilan Melnick shares early adopter lessons on xanomeline-trospium in schizophrenia: first-episode use, GI side effect management, and cross-titration.
,
Negative Symptoms May Predict Who Responds to Xanomeline-Trospium in Schizophrenia
Expert Commentary

Negative Symptoms May Predict Who Responds to Xanomeline-Trospium in Schizophrenia

October 8, 2026

Mike Halassa describes negative symptoms in schizophrenia and discusses clinical and post-hoc evidence that potentially suggests negative symptoms may be a useful clinical feature to look for when considering…
JCP
A Trauma Expert's View on Psychedelic Medicine with Steven Berkowitz, MD
Podcast

A Trauma Expert’s View on Psychedelic Medicine with Steven Berkowitz, MD

October 6, 2026

Dr. Steven Berkowitz discusses childhood trauma, the CFTSI early intervention model, trauma in autistic youth, and psychedelic research in youth with PTSD.
,
Negative Symptoms and Xanomeline-Trospium: What Trials and Practice Data Can and Cannot Show
news

Negative Symptoms and Xanomeline-Trospium: What Trials and Practice Data Can and Cannot Show

October 5, 2026

Negative-symptom scores fell on xanomeline-trospium in schizophrenia trials, but how much reflects treatment, especially in stable illness, remains unclear.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe